HOME >> BIOLOGY >> NEWS
Study provides direct evidence of the role of telomeres in prostate cancer development

Boston, MA (October 16, 2002) Telomere shortening has been proposed as an early and prevalent marker of prostate cancer process, according to a study presented today at the American Association for Cancer Research's first annual Frontiers in Cancer Prevention Research meeting. Findings of the study provide the first direct evidence that human prostate cancer may progress, in the earliest phase, via chromosomal instability generated by short telomeres, by revealing that telomere shortening is a defining DNA alteration characterizing early prostate cancer lesions.

Telomere shortening may cause significant alterations at the chromosomal level of tumors initiating chromosomal instability and causing progression to a fully malignant state. Telomeres are specialized structures located at the end of chromosomal arms that stabilize and protect chromosomes. In addition, they play a role in preventing cells from reproducing uncontrollably.

"Our study found that short telomeres may represent useful markers for assessing effectiveness in cancer chemoprevention studies," according to Alan Meeker, research fellow and lead investigator of the study which was conducted by researchers at the Brady Urological Institute and Department of Pathology, The Johns Hopkins University School of Medicine. "In addition, if telomere shortening does play a direct, causal role in the cancer process, then it represents an important prevention target in its own right."

In order to test the hypothesis that telomere shortening is an early contributor to human prostate cancer, the researchers developed and validated a new test that allows direct assessment of telomere length in clinical specimens. This study probed telomere lengths in high-grade prostatic intraepithelial neoplasia (HGPIN), the pre-invasive precursor to prostate cancer. Results showed that the telomere lengths of epithelial cells (relating to cellular tissue) within HGPIN lesions were strikingly shorter t
'"/>

Contact: Aimee Frank
AMF@spectrumscience.com
202-369-1654
American Association for Cancer Research
16-Oct-2002


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
(Date:3/9/2016)... Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> DERMALOG, the biometrics ...
(Date:3/3/2016)... 3, 2016  FlexTech, a SEMI Strategic Association Partner, ... Research & Development, Leadership in Education, and, in a ... 9 th year of the FLEXI Awards and ... individuals from past years . Judging was done ... set of criteria, by a panel of non-affiliated, independent, ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, ... the National Stroke Association during National Stroke Awareness Month in May. An ... pages throughout the month. CereScan will donate $1 up to a maximum ...
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to announce ... , Doug began his career at PBI-Gordon in February 1988, after finishing his masters ... of roles, ranging from customer service to national product manager, to helping develop, name ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... enterprise talent development, skill-building and compliance training platform on mobile devices, today ... course: Overview of Regulatory Requirements for Medical Devices. The course is essential for ...
Breaking Biology Technology:
Cached News: